Scientists at Hirosaki University, Medical Department discuss research in pediatrics
2007 NOV 22 -- According to recent research from Hirosaki, Japan, "Since a proportion of systemic-onset juvenile idiopathic arthritis (SOJIA) patients continue to require long-term corticosteroid therapy for disease control, an effective and safe therapeutic strategy for controlling the activity of refractory SOJIA remains to be established." "We report the efficacy of tacrolimus for the treatment of SOJIA in two patients with refractory SOJIA, one of them showing poor response to cyclosporine A. Tacrolimus might be the treatment of choice in selected patients with refractory systemic-onset juvenile idiopathic arthritis," wrote H. Tanaka and colleagues, Hirosaki University, Medical Department. The researchers concluded: "Further studies to confirm the long-term efficacy and safety of tacrolimus in larger numbers of patients are, however, needed." Tanaka and colleagues published their study in European Journal of Pediatrics (Treatment of difficult cases of systemic-onset juvenile idiopathic arthritis with tacrolimus. European Journal of Pediatrics, 2007;166(10):1053-1055). For additional information, contact H. Tanaka, Hirosaki University, School Medical, Dept. of Pediatrics, 5 Zaifu Cho, Hirosaki, Aomori 036, Japan. Publisher contact information for the European Journal of Pediatrics is: Springer, 233 Spring Street, New York, NY 10013, USA. Keywords: Japan, Hirosaki, Life Sciences, Pediatric, Pediatrics, Hirosaki University, Medical Department. This article was prepared by Medical Verdicts & Law Week editors from staff and other reports. Copyright 2007, Medical Verdicts & Law Week via NewsRx.com.
|
